NCT04509596: DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer

NCT04509596
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with CNS complications that require urgent neurosurgical intervention
https://ClinicalTrials.gov/show/NCT04509596

Comments are closed.

Up ↑